Trial Profile
Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Relapsed/Refractory Multiple Myeloma Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacodynamics
- 29 Oct 2020 Status changed from active, no longer recruiting to completed.
- 24 Jul 2018 Planned End Date changed from 1 Aug 2018 to 1 May 2021.
- 05 Jul 2018 Planned End Date changed from 1 May 2018 to 1 Aug 2018.